OBJECTIVES: In Brazil, the concepts of minimization cost are being applied in price analyses of new pharmaceuticals since 2004, when was published the Resolution of Brazilian Chamber of Economic Regulation of Pharmaceuticals (CMED) n° 2/2004. The drugs are divided in two types: new drugs presentations and new molecules, these are classified by two categories: I - New product with patent of molecule, which has scientific evidences of benefits over the medications used on the same treatment; II - New products which were not classified as category I. The prices analyses of new drugs are classified by two methods: the lowest international price and cost of treatment considering an existing medication traded in Brazil. The category I take in the consideration the lowest international price and the category II considering the cost of treatment and international price, the lowest of them. The goal of this research is to evaluate the price regulation of new molecules over the last eight years and all the consequences in terms of prices and a decrease of costs for the society. METHODS: Only data of prices analyses assessed by Office of Economic Assessment of New Technologies of Brazilian Health Surveillance Agency (Anvisa), which supports the decisions of CMED, were evaluated. RESULTS: According to our statistics, 209 new molecules - category I and II - (over 563 presentations) were analyzed. During the last eight years, the difference between the price proposed by the laboratories and the price analyzed by Anvisa has been reduced, as demonstrated bellow: Category I 21%; Category II 39%. CONCLUSIONS: It suggests the prices are more in conformity of the resolution. In fact, the Resolution CMED n° 2/2004 brought rational price decrease and, in consequence, cost decrease for the private and public sector, improving the efficiency of health care.